An Engineered Contact Lens for Passive and Sustained Release of Lifitegrast, an Anti-Dry Eye Syndrome Drug
Abstract
Lifitegrast is an FDA-approved drug that inhibits T-cell mediated inflammation associated with dry eye syndrome (DES). Lifitegrast is a potent inhibitor of the interaction between LFA-1 on T-cells and ICAM-1 on endothelial cells at the ocular surface. While effective in treating DES, 5% (81.2 mM) lifitegrast has low drug utilization and elicits off-target effects. Here we engineer contact lenses to release therapeutically-relevant doses of lifitegrast to every tear film for up to 10-hours. Lifitegrast is coupled to the polymer of the soft hydrogel lens via a photolabile (caged) crosslinker. Exposures of the lens to the 400-430 nm wavelengths of indoor daylight excite the caged crosslinker molecules and trigger a bond-cleavage reaction that releases authentic lifitegrast passively to the tear film. The photoproduct of the reaction remains chemically-linked to the polymer of the single-use lens. Our studies show that passive exposures of the lens to indoor light would generate an average of 990 nM lifitegrast to every tear film in a zero-order reaction for up to 10-hours. This concentration exceeds the Kd for the interaction between ICAM-1 and LFA-1 by [~]330-fold and would sustain inhibition of inflammatory responses at the ocular surface. The amount of lifitegrast released from the lens increases during exposures to outdoor sunlight. Over a 10-hour exposure to indoor light, a single lens would release 0.44% of the lifitegrast present in two drops of commercial 5% lifitegrast. Compared to tear-drop approaches, our engineered lenses would sustain the passive delivery of therapeutically-relevant doses of lifitegrast over a longer period, and exhibit improved drug utilization at a lower cost. Our technology could easily be integrated into daily-use contact lenses in order to prevent inflammation at the ocular surface, dry-eye and contact lens-mediated discomfort. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=198 HEIGHT=200 SRC="FIGDIR/small/439289v1_ufig1.gif" ALT="Figure 1"> View larger version (75K): org.highwire.dtl.DTLVardef@1049076org.highwire.dtl.DTLVardef@a83fceorg.highwire.dtl.DTLVardef@1f52c4borg.highwire.dtl.DTLVardef@12f0ead_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Proteoglycan 4 (PRG4) expression and functionin dry eye associated inflammation
N. G. Menon, R. Goyal, … T. A. Schimdt·bioRxiv·Oct 1, 2020
- A T-cell engager platform induces deep plasma cell depletion in autoimmune dry eye
Jie Ling, Dongliang Wang, … Yingfeng Zheng·Cell Reports MedicinePeer-reviewed·Oct 1, 2026
- Laser-activated drug implant for controlled release to the posterior segment of the eye
- A CXCR3-activating peptide increases Tear Break Up Time and corrects corneal haze in a rabbit model of environmental dry eye
A. Wells, Y. Wang, … S. K. Swamynathan·bioRxiv·Dec 7, 2022
- Lipidomic Analysis Reveals Drug-Induced Lipoxins in Glaucoma Treatment
David J. Mathew, Shubham Maurya, … Jeremy M. Sivak·JCI InsightPeer-reviewed·Feb 24, 2026
- A synthetic tear protein resolves dry eye through promoting corneal nerve regeneration.
Y. Efraim, F. Y. T. Chen, … S. M. Knox·bioRxiv·May 7, 2022